Since 1946 a number of reports have appeared on the use of urethan (ethyl carbamate) in the treatment of various malignant diseases, including multiple myeloma, The results from treatment of the first few patients with multiple myeloma were not encouraging.1 In 1947, however, Alwall2 reported his findings in two patients, one of whom experienced almost complete recovery, both objectively and subjectively, upon prolonged treatment with urethan. The hemoglobin content, erythrocyte count, erythrocyte sedimentation rate, total serum proteins, and albumin-globulin ratio returned to normal; albuminuria disappeared; plasma myeloma cells disappeared from the sternal marrow, and only unchanged roentgenograms remained as evidence of the original process. Subsequent reports by Loge and Rundles,3 Harrington and Moloney,4 and others5 have been encouraging, but none matched the dramatic result recorded by Alwall.
METHOD OF STUDY
From January, 1948, through June, 1950, urethan was administered to 66 patients, about two-thirds of
Luttgens WF, Bayrd ED. TREATMENT OF MULTIPLE MYELOMA WITH URETHAN: EXPERIENCE WITH SIXTY-SIX CASES OVER A TWO-AND-A-HALF-YEAR PERIOD. JAMA. 1951;147(9):824–827. doi:10.1001/jama.1951.03670260026008
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: